Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of KeyMed Biosciences's CMG-901?
CMG-901 is a monoclonal antibody conjugated commercialized by KeyMed Biosciences, with a leading Phase III program in Adenocarcinoma Of The...
Data Insights
Risk adjusted net present value: What is the current valuation of AstraZeneca's CMG-901?
CMG-901 is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase III program in Adenocarcinoma Of The Gastroesophageal...